Cutting time and operation costs of biopharmaceuticals by revolutionising their manufacturing process

The AMECRYS project targets to boost medical advancement and efficiency in biopharmaceutical productions by revolutionising the Downstream Processing (DSP) operations in the manufacture of biopharmaceuticals. The idea is to achieve the separation and purification of therapeutic proteins with innovative membrane crystallization technology overcoming chromatography with all of its disadvantages as well as costs. The research activity is focused on the downstream processing of monoclonal antibodies (mAbs), one of the most important class of therapeutic proteins in modern medicine, which are used in a wide range of diseases including cancer, cardiovascular, autoimmune, and inflammation.